Moteur de recherche d’entreprises européennes
Financement de l’UE (196 708 €) : RErestaurer la capacité de réparation myocardique via la modulation de la sécrétion de cytoKINe médiée par MAcrophage. Hor04/05/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
RErestaurer la capacité de réparation myocardique via la modulation de la sécrétion de cytoKINe médiée par MAcrophage.
Type-2 diabetes (T2D) is a chronic condition strongly associated with cardiovascular diseases, mainly recurrent myocardial infarctions (MI), and generating enormous healthcare cost. Macrophages orchestrate the remodelling of the heart post-MI by efferocytosis-mediated cytokine secretion. Specifically, Mertk-mediated efferocytosis promotes vessel formation, tissue reperfusion and resolution of the inflammatory response via the secretion of the anti-inflammatory cytokines interleukin-10 (IL-10) and Vascular Endothelial Growth Factor-A (VEGF-A). In IR/T2D, efferocytosis-mediated cytokine secretion is impaired, leading to chronic inflammation, adverse post-MI remodelling, recurrent heart failure and excessive mortality. To date, the signalling and intracellular trafficking pathways leading to cytokines secretion are unknown, and the mechanisms of impairment during IR/T2D are unexplored. Previous therapeutic strategies focussed on repairing damaged tissue by injection of progenitor cells or modulating inflammation by cytokine injection, but both strategies gave disappointing results. In this proposal, I will define the mechanisms of efferocytosis-mediated cytokine secretion in macrophages, investigate their defects in IR/T2D and test a novel cell-based therapeutic strategy for improving recovery of T2D patients post-MI and preventing recurrence of cardiac events by restoring cytokine secretion in diabetic macrophages.
| Institut National de la Sante et de la Recherche Medicale | 196 708 € |
https://cordis.europa.eu/project/id/846519
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Institut National de la Sante et de la Recherche Medicale, Paris.
